The malignant pleural effusion market is expected to witness steady growth over the coming years, driven by the increasing incidence of metastatic cancers, particularly lung, breast, and ovarian cancers. Rising awareness, improved diagnostic techniques, and advancements in minimally invasive drainage and pleural management procedures are contributing to market expansion. Additionally, the launch of emerging therapies such as PTS500 (Gongwing Biopharm), M701 (Wuhan YZY Biopharma), RSO-021 (RS Oncology), and others will further propel the market growth.
The malignant pleural effusion market is expected to witness steady growth over the coming years, driven by the increasing incidence of metastatic cancers, particularly lung, breast, and ovarian cancers. Rising awareness, improved diagnostic techniques, and advancements in minimally invasive drainage and pleural management procedures are contributing to market expansion. Additionally, the launch of emerging therapies such as PTS500 (Gongwing Biopharm), M701 (Wuhan YZY Biopharma), RSO-021 (RS Oncology), and others will further propel the market growth.